吉贝尔继续加码干细胞布局 卡位行业商业化临界点

Core Insights - The company Jibeier (688566.SH) is actively investing in the cell therapy sector, recently participating in a financing round for Shanghai Aisaar Biotechnology Co., Ltd. to capitalize on the upcoming commercialization opportunities in the industry [1] - Aisaar Biotechnology's core product, human umbilical cord mesenchymal stem cell (IxCell hUC-MSC-O) injection, is in Phase III clinical trials for treating knee osteoarthritis, showcasing promising efficacy from previous Phase II trials involving nearly 200 cases [1] - The stem cell therapy market is expected to undergo significant growth, with projections indicating that the global cell therapy market could reach $113.53 billion by 2032, growing at a compound annual growth rate (CAGR) of 23.17% [3] Company Developments - Jibeier has previously invested 81.2 million yuan in Zhejiang Shengchuang Precision Medical Technology Co., Ltd., acquiring a 10.91% stake and actively participating in governance [1] - Shengchuang Technology's self-developed "Menstrual Blood Mesenchymal Stem Cell Injection" (SC01009) has received clinical trial approval for treating decompensated liver cirrhosis post-hepatitis B, marking its fourth new drug registration clinical trial (IND) approval [2] - The unique advantages of the menstrual blood-derived stem cell product include non-invasive collection, rapid proliferation, and low immunogenicity, making it suitable for industrialization and large-scale cultivation [2] Industry Trends - The existing treatments for idiopathic pulmonary fibrosis (IPF) have limited efficacy, with current drugs only able to slow disease progression, while lung transplants face donor shortages [3] - The global IPF drug market is projected to grow at an annual rate exceeding 15%, potentially surpassing $10 billion by 2030, indicating a lucrative opportunity for cell therapies [3] - The domestic stem cell therapy sector is at a critical turning point, with six therapies entering Phase III trials, reflecting a significant increase in clinical advancements after over a decade of technological accumulation [3]